Physician profile
Mandi L Beman
NPI 1154467793
$28,725.92
in general payments reported to CMS, 2019-2025
23 companies · $3,201 in 2025
The $3,201 reported for 2025 was more than what 92% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,551 · 2021: $2,980 · 2022: $827 · 2023: $436 · 2024: $2,069 · 2025: $3,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,038 · Education: $1,500 · Food and Beverage: $700 · Travel and Lodging: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,037.50 |
| Education | $1,500.00 |
| Food and Beverage | $700.34 |
| Travel and Lodging | $468.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,028.95 | 2019-2022 | |
| Hologic Sales and Service, LLC | $6,273.69 | 2021-2025 | Myosure Tissue Removal Device, Acessa Provu System, Omni Hysteroscope |
| Intuitive Surgical, INC. | $2,049.07 | 2022-2024 | Da Vinci Surgical System |
| Gynesonics, INC. | $383.26 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Bolder Surgical LLC | $200.00 | 2019 | |
| Covidien LP | $111.14 | 2019 | |
| Pfizer INC. | $85.02 | 2021-2023 | |
| Coloplast Corp | $68.98 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.41 | 2020-2025 | |
| Myovant Sciences INC. | $56.30 | 2021-2022 | |
| Channel Medsystems, INC. | $56.12 | 2022 | |
| Organon LLC | $52.71 | 2023-2024 | Nexplanon, Nuvaring |
| Meditrina | $49.67 | 2021-2024 | |
| Coopersurgical, INC. | $41.27 | 2021-2022 | |
| Baxter Healthcare | $39.62 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.57 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $25.24 | 2021-2022 | |
| Olympus America INC. | $22.67 | 2024 | Olympus |
| Roche Diagnostics Corporation | $20.64 | 2021 | |
| Exeltis, USA INC. | $19.49 | 2024 | Slynd |
| Ethicon US, LLC | $15.36 | 2022 | |
| Innovation Technologies INC | $15.20 | 2024 | Irrisept |
| Boston Scientific Corporation | $13.54 | 2023 | Obtryx System - Curved |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandi Beman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.